Utilization trends for GLP1s (glucagon-like peptides, used to treat diabetes and sometimes obesity) will continue to increase in 2024, adding cost to the system and pressure on payers and employers to cover treatments.
The growing use of GLP1s will have a major industry impact.
Utilization trends for GLP1s (glucagon-like peptides, used to treat diabetes and sometimes obesity) will continue to increase in 2024, adding cost to the system and pressure on payers and employers to cover treatments.
See how rule of three’s strategic services can support you and your healthcare team.